Hollis-Eden Receives Clearance From South African Government to Initiate a Clinical Trial with Transmucosal (Buccal) Formulation of Investigational Drug HE2000.
SAN DIEGO, March 21 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced it has received clearance from the South African Medicines Control Council (MCC) to initiate testing of a new transmucosal (buccal) formulation of the Company's lead investigational drug candidate HE2000 in treatment naive HIV infected...

Antigenics Receives NIH Grant for Malaria Study.
NEW YORK, April 5 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN) today announced that it has been awarded a grant from the National Institutes of Health (NIH) to advance the development of a vaccine for the prevention of malaria. This development work will be based on the company's...

Filling you in on amalgam.
One of the more troublesome medical controversies that flare up on occasion concerns the safety of amalgam fillings used in dentistry. Some dentists-a small but vocal minority-assert that there is a clear and present danger in mercury, which comprises about 50% of each filling (the other half consisting of...

Detecting Early Signs of CELLULAR DAMAGE.
Screening tests that detect the earliest signs of cellular damage leading to various immune function disorders and cancer have been developed by Immunosciences Lab., Inc., Beverly Hills, Calif. "We believe that Intervention at the earliest stages of cellular damage can prevent many cancers and other immune disorders from progressing,"...

The body bazaar.
Blood, kidneys, eggs, sperm--name a body part, there's a price on it. Think of it as a commodities market for the twenty-first century. There's a bank in central Boston that offers its customers a unique investment opportunity. For an initial outlay of $2,500 and yearly fees of $95, investors...

Regenerative medicine breakthroughs: will BioTime reset the clock of aging?
Rapid advances in the field of stem cell therapeutics are bringing us closer to the elusive goal of harnessing the "immortal flame" that survives in all of us. Indeed, it has become clear that, in the words of internationally known gerontology researcher Dr. Michael West, "You and I are...

MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks.
HORSHAM, Pa., Nov. 12 /PRNewswire/ -- Centocor, Inc. announced today the launch of MEDVERSATION(TM) (http://www.medversation.com/), an extensive web-based resource designed to facilitate more-informed conversations between U.S. physicians and their patients about the efficacy and safety of REMICADE(R) (infliximab). This interactive web application, in development for the past...

Umbilical Cord Blood Stem Cell Use Increases.
The stem cells likely to yield the quickest, least expensive, and largest clinical benefit are readily available and present no ethical dilemma. They are umbilical cord blood stem cells. The controversy surrounding President Bush's decision to fund research involving existing lines of embryonic stem cells has dominated...

Fluxion Biosciences Takes R&D 100 Award.
HEALTH AND BEAUTY CLOSE-UP-7 July 2008-Fluxion Biosciences Takes R&D 100 Award(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Fluxion Biosciences, a provider of functional cell biology systems for life science research and drug discovery, announced that it has won a 2008 R&D 100 Award for its BioFlux 200 System. ...

Ichor Shareholders Approve Change of Name To Mymetics and Expand the Board of Directors.
New Name Reflects a Science Strategy Against Viral Mediated Autoimmune Diseases LYON, France, July 31 /PRNewswire/ -- Ichor Corporation (OTC Bulletin Board: ICHR.OB) announced today that it has approved a change of its corporate name to Mymetics Corporation and will begin trading on...